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The essential function of the kidney is to ensure formation of a relatively protein-free ultra-
filtrate, urine.The rate of filtration and composition of the primary renal filtrate is determined
by the transport of fluid and solutes across the glomerular filtration barrier consisting of
endothelial cells, the glomerular basement membrane, and podocyte foot processes. In
diabetes mellitus (DM), components of the kidney that enable renal filtration get struc-
turally altered and functionally compromised resulting in proteinuria that often progresses
to end-stage renal disease. Histological alterations in DM include early hypertrophy of
glomerular and tubular components, subsequent thickening of basement membrane in
glomeruli and tubules, progressive accumulation of extracellular matrix proteins in the
glomerular mesangium and loss of podocytes, together constituting a clinical condition
referred to as diabetic nephropathy (DN).The glomerulus has become the focus of research
investigating the mechanism of proteinuria. In particular, the progressive dysfunction and/or
loss of podocytes that is contemporaneous with proteinuria in DN have attracted intense
scientific attention. The absolute number of podocytes predicts glomerular function and
podocyte injury is a hallmark of various glomerular diseases. This review discusses the
importance of podocytes in normal renal filtration and details the molecular and cellular
events that lead to podocyte dysfunction and decreased podocyte count in DN.
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INTRODUCTION
The kidneys regulate electrolyte, water, and acid–base balance and
are thus indispensible for the maintenance of body homeosta-
sis. These functions are carried out by the collective action of
~1 million nephrons in each kidney. Each nephron consists of
a glomerulus and a renal tubule. The glomerulus is responsible
for filtering water and small molecules from circulating plasma,
while the tubular system regulates their selective reabsorption and
secretion thus dictating the final composition of urine. Under nor-
mal conditions, the vertebrate kidneys ensure almost protein-free
ultra-filtrated urine with tightly regulated composition. How-
ever, in disease conditions, owing to an array of abnormalities
in glomerular filtration, varying amounts of plasma protein get
excreted in urine. Protein concentration in urine is indexed by
measuring albumin levels collected for 24 h and albuminuria is a
well-known predictor of adverse renal outcome. As per the Amer-
ican Diabetic Association guidelines, microalbuminuria is defined
as levels of albumin ranging from 30 to 300 mg in a 24-h urine
collection (1). Macroalbuminuria or proteinuria is defined as a uri-
nary albumin excretion of≥300 mg/24 h. If left untreated, the con-
dition of macroalbuminuria often progresses to end-stage renal
disease (ESRD) warranting dialysis or renal transplant therapy.
Diabetes mellitus (DM) is a group of metabolic diseases character-
ized by hyperglycemia resulting from defects in insulin secretion,
insulin action, or both (2). Chronic hyperglycemia in DM is associ-
ated with long-term damage, dysfunction, and failure of different
organs, especially eyes, kidneys, nerves, heart, and blood vessels
(2). Diabetic nephropathy (DN) is a major chronic complication
in diabetic subjects that develops in 20–40% of patients with Type
1 or Type 2 DM (3). Prominent early renal changes in DM include
glomerular hyperfiltration, renal hypertrophy, and microalbumin-
uria. With advancement of the renal involvement in DM, there is
a significant decrease in glomerular filtration rate (GFR) and the
development of macroalbuminuria that often progresses to ESRD.
In the US, DN is the most common cause of ESRD accounting for
~54% of new cases of ESRD (3).
The original histological description by Kimmelstiel and Wil-
son emphasized an increase in mesangial matrix (hyalinization)
as the major characteristic of renal injury in DM (4). For several
decades, mesangial cells were the focus of intensive research on
the assumption that changes in mesangial cells could provide the
cellular and molecular basis for DN. Transforming growth factor-
β1 (TGF-β1) mediates proliferation and hypertrophy of mesangial
cells thus contributing to the glomerular hypertrophy in DM (5, 6).
Mesangial matrix expansion with accumulation of matrix in the
mesangial area reduces the capillary surface area available for filtra-
tion, correlates with proteinuria, and contributes to the progressive
loss of renal function (7–9). However, the genesis of proteinuria
in DM is not readily explained by the associated mesangial matrix
expansion. Appearance of protein in the urine and other early fea-
tures in DN indicate damage to the glomerular filtration barrier
(GFB). Therefore, a “mesangiocentric” dogma explaining diabetic
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proteinuria cannot easily explain the pathogenesis of the disease
and consideration should be given to alterations of the GFB in
DM. The GFB of kidney is a size and shape dependent selective
molecular sieve that tightly regulates the filtration of large macro-
molecules while allowing passage of small molecules and water.
The three components that constitute GFB are the fenestrated
glomerular endothelium, the glomerular basement membrane
(GBM), and the visceral epithelial cells or podocytes (Figure 1).
There is much debate as to the role of each of the components of
glomerulus in the pathophysiology of proteinuria in DN. Deckert
et al. proposed that endothelial dysfunction (microangiopathy)
is a causal factor in the pathogenesis of proteinuria (10). Colla-
gen accumulation and thickening of GBM during DM and loss
of charge selectivity in the GBM has also been proposed to partly
explain the proteinuria (11, 12). However, a decrease in nega-
tively charged proteoglycans of GBM occurs late in the course of
DN, sometimes long after the appearance of microalbuminuria,
suggesting a role for the other components of the GFB in the
pathogenesis of proteinuria in DN (13).
The final barrier that restricts entry of plasma proteins from
the circulation into the urine is the podocyte. Whereas all the
three components of GFB are required for normal renal filtration,
data obtained over the past decade has highlighted the crucial
role of podocytes in this filtering process (14). Studies in both
patients with DM and animal models of DM revealed that onset
of proteinuria is associated with decreased density and altered
morphology of the podocytes (15, 16). Reduction in podocyte
number has been shown to predict progressive decline in renal
function and proteinuria in Pima Indians with type 2 DM (17).
Studies by Peterman et al. in streptozotocin-induced diabetic rats
suggest that podocytes detach from GBM into urinary space (18).
Furthermore, podocytes in urine are viable and can be cultured
(19, 20). A key feature of the podocyte that differentiates it from
other components of the GFB is lack of a proliferative mecha-
nism in response to injury; mesangial and glomerular endothelial
cells readily proliferate in response to injury caused by an array of
insults (21, 22). Thus, podocytes exit the cell-cycle to remain termi-
nally differentiated with a quiescent phenotype. It is hypothesized
that with loss of a critical proportion of the podocyte population
from the glomerulus, the remaining cells are unable to compensate
for the glomerular filtration function and this results in glomeru-
losclerosis (23). Two mechanisms are proposed to explain the
loss of podocytes: (i) apoptosis and (ii) detachment. Apoptosis
of podocytes was proposed as a mechanism of podocyte loss and
glomerulosclerosis in TGF-β1 transgenic mice, CD2AP−/− mice
and puromycin aminonucleoside (PAN)-treated rats (24–26) and
it has been argued that ~90% of podocytes detected in urine are
apoptotic (15). However, if this is the case, it is not clear how
podocytes from urine could be viable and can be cultured. Alterna-
tively, a decreased podocyte count could be explained by impaired
podocyte adhesion to the GBM. Evidence for this mechanism is
provided by data showing elevated expression of anti-adhesive
proteins and integrin receptors in DN (18, 20, 27, 28). Since reduc-
tion in podocyte density and urinary excretion of podocytes is an
early pathological feature in patients with DM and animal mod-
els of DM (29–31), podocyte depletion could be considered as
a hallmark of human and experimental DN. Although, several
observations identify podocyte depletion as one of the earliest
FIGURE 1 | Cartoon depicting the architecture of the glomerulus
filtration barrier, which is composed of three layers: the endothelium,
glomerular basement membrane, and podocytes. Podocytes extend
numerous lamellipodia that branch into primary and secondary processes,
which further ramify into smaller foot processes. Foot processes from
neighboring podocytes interdigitate and are connected by a modified
adherent junction called slit-diaphragm (SD) that provides intercellular space
for the passage of glomerular filtrate.
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cellular features of DN, the molecular pathways and pathological
mechanism(s) that manifest as decreased podocyte count in DM
have only been partially characterized. In this review, we discuss
the importance of podocytes in normal renal filtration and sum-
marize systemic, cellular, and molecular events that underlie the
dysfunction and/or loss of podocytes in DM.
THE FUNCTION OF PODOCYTES
Podocytes are highly branched, terminally differentiated visceral
epithelial cells of the renal glomerulus that cover the urinary side
of the GBM and play a crucial role in the regulation of glomeru-
lar function. Podocytes account for about 30% of all glomerular
cells. The first description of podocyte was by Karl Zimmerman
in 1929 (32). He described a heavily branched cell type within the
renal glomerulus. The unique architecture of podocytes includes
a voluminous cell body with all major organelles, major (primary)
processes, and a large number of secondary processes or foot
processes. The major processes are composed of microtubules and
vimentin intermediate filaments, while the foot processes are made
of actin filaments. The actin cytoskeleton of the foot processes
plays a critical role in the attachment of podocytes to the GBM,
which together constitute a contractile apparatus that counter-
acts the expansive forces of the vasculature (33). Foot processes of
neighboring podocytes are connected with an adherent junction
named a slit-diaphragm (SD), which represents the only cell–cell
contact between podocytes. The SD dictates the glomerular perms-
electivity and is freely permeable to water and small solutes but is a
size selective barrier to the passage of large molecular weight mol-
ecules. Several proteins (Nephrin, CD2-associated protein, ZO-1,
podocin, P-cadherin) determine the SD structure and enable it to
act as a size and shape selective glomerular barrier. The podocyte
surface is divided into two parts: the apical membrane and the
basal membrane, which are above and below the SD, respectively.
The apical membrane of podocyte is strongly negatively charged
due to the presence of the glycoprotein glycocalyxin. Glycocalyxin
repels negatively charged serum albumin and keeps adjacent FPs
separated from each other (34). The basal membrane of podocytes
mediates its anchorage to GBM via integrins.
Alteration in the morphology of the podocytes from the dis-
ruption of foot process architecture or the loss of entire podocytes
is associated with significant proteinuria in glomerular diseases
including DN (35–37). In DN, podocyte number is markedly
reduced (with associated podocyturia), the foot process width
is significantly widened, and the SD becomes narrower as the
GFR declines (17, 29, 31, 37). The space between the underside
of podocyte cell body/primary processes and the foot processes,
referred to as the sub-podocyte space, covers 50–65% of the fil-
tration surface of the GFB. The sub-podocyte space contributes
to both ultrafiltration and hydraulic resistance and thus plays an
important role in glomerular permeability. Significant podocyte
injury and dysfunction in DM may is associated with foot process
retraction and flattening (known as effacement), which enhances
the loss of protein into the primary urine by altering the area and
architecture of the sub-podocyte space (38).
A landmark in podocyte biology was the study that dis-
covered mutations in nephrin (NPHS1) as a cause of congen-
ital nephrotic syndrome in humans, characterized by massive
proteinuria in utero and nephrosis at birth (39). Subsequent stud-
ies localized nephrin to the SD of podocytes and suggested that
nephrin also acts as a signaling molecule, controls cytoskeletal
architecture, and impact the shape and viability of podocytes.
Appropriate level of expression of nephrin is necessary for normal
glomerular function. Thus, in addition to diseases caused by muta-
tions in NPHS1, reduction in NPHS1 expression is also closely
associated with the development of albuminuria, as observed in
experimental models of both diabetes and hypertension (40, 41).
Mutations in a number of other genes were subsequently identified
as being associated with proteinuria and podocyte abnormalities;
these include podocin (NPHS2), α-actinin-4 (ACTN4), laminin
β2 (LAMB2), transient receptor protein 6 ion channel (TRPC6)
and phospholipase Cε1 (PLCE1). In addition to serving as a size
selective barrier, podocytes offer back-up support for capillaries
to filter efficiently and also synthesize components of GBM (type
IV collagen). Both, quantity and quality of the podocyte are crit-
ical in maintaining permselectivity of the glomerular filtration.
Podocyte injury is the leading causes of chronic kidney disease
in patients requiring renal replacement therapy (42). Podocytes
are exposed to various noxious stimuli in DM such as high glu-
cose, fatty acids, growth factors, cytokines, and hormones. It is
generally believed that podocytes are terminally differentiated
non-regenerative cells with limited healing capacity. Thus, apop-
tosis leads to an irreversible decrease in the number of podocytes
and the filtration barrier becomes incomplete, allowing blood pro-
teins to penetrate this filtration membrane. Although podocytes
are visceral epithelial cells, they also express mesenchymal markers.
Podocyte transition to a more mesenchymal nature can result in
their detachment and loss from GBM and consequent impairment
of renal filtration.
DIRECT EFFECT OF HYPERGLYCEMIA ON PODOCYTE
APOPTOSIS VIA INCREASE IN OXIDATIVE STRESS
One of the major consequences of DM is hyperglycemia. There
is a strong case for hyperglycemia injuring podocytes and per-
turbing their structural integrity, viability, and normal function.
Podocytes express glucose transporters (GLUT1 and 4) and treat-
ment with insulin increased the glucose uptake predominantly via
GLUT4 (43). It was shown, both in vivo and in vitro, that high
glucose induces podocyte apoptosis and contributes to reduced
podocyte number (44). Susztak et al., were the first to report
that in podocytes elevated concentration of extracellular glu-
cose increased reactive oxygen species (ROS) via NADPH oxidase
and induced apoptosis by activation of mitogen activated pro-
tein kinase (MAPK) and the caspase-3 cascade (44). Podocyte
apoptosis increases with onset of hyperglycemia in both type 1
and type 2 DM models and podocyte apoptosis coincides with
the onset of albuminuria (44). Inhibition of NADPH oxidase
activity with apocyanin prevented podocyte apoptosis and resul-
tant albuminuria (44). Eid et al. further elaborated the mecha-
nism of glucose mediated apoptosis of podocytes by demonstrat-
ing that high glucose induces ROS via sequential upregulation
of cytochrome p450, its metabolite 20-hydroxyeicosatetraenoic
acid (20-HETE), subsequent increase in the NADPH oxidase
(Nox1 and Nox4) expression, and NADPH-dependent superox-
ide anion generation (45). It was also shown that treatment
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of podocytes with 20-HETE mimicked the effect of high glu-
cose and induced podocyte apoptosis. Inhibition of cytochrome
P450A (CYP4A) in OVE26 mice (type 1 DM model) prevented
oxidative stress and reduced both foot process effacement and
apoptosis and significantly decreased albumin excretion (45). A
mechanistic basis for high glucose-induced apoptosis of podocytes
was shown by a study that demonstrates high glucose-induced
ROS and activates TRPC6 resulting in intracellular Ca2+overload
and apoptosis (46). In another study, it was reported that expo-
sure of podocytes to high glucose increased intracellular Ca2+
concentration, leading to activation of calcineurin and subse-
quent nuclear accumulation of nuclear factor of activated T-
cells (NFAT2) and Bax expression (47). It is noteworthy that
inhibition of NFAT2 ameliorates podocyte injury and DN in
db/db mice (48). Wang et al. showed that hyperglycemia induces
Rho-associated coiled-coil-containing protein kinase1 (ROCK1)
expression and regulates mitochondria fission by promoting
phosphorylation and translocation of dynamin-related protein-1
(Drp1) into the mitochondria (49). Deletion of ROCK1 in diabetic
mice prevented mitochondrial fission, whereas podocyte-specific
cA-ROCK1 mice exhibited increased mitochondrial fission (49).
Mitochondrial fission and consequent generation of mitochondr-
ial ROS are implicated in podocyte apoptosis. Thus, an increase
in podocyte ROS levels is considered a potential mediator of
podocyte apoptosis in DM.
Inappropriate activation of the local renin–angiotensin-system
(RAS) within the kidneys is also associated with renal injury.
Hyperactivated RAS contributes to the elevated intraglomeru-
lar capillary pressure, promoting podocyte apoptosis in an
angiotensin subtype 1 receptor (AT1R)-dependent fashion. Defin-
itive evidence for a role for AT1R mediated signaling in podocy-
topathy comes from the transgenic AT1R-overexpressing rat,
which spontaneously develops podocyte injury, proteinuria, and
glomerulosclerosis. Pharmacologic inhibition of angiotensin II
abrogates loss of nephrin and prevents foot process effacement.
In addition, angiotensin receptor antagonists attenuated VEGF
expression in diabetic rats and prevented the development of pro-
teinuria. A direct role for hyperglycemia in the activation of RAS
in podocytes and its implications for podocyte apoptosis was pro-
vided by a study by Durvasula and Shankland (50). They showed
that exposure of podocytes to high glucose resulted in increases
of angiotensin II levels via increased renin activity and AT1R
levels (50).
One of the changes that occur as a result of elevated blood
glucose in DM is the generation and accumulation of advanced
glycation endproducts (AGEs). Both AGEs and their receptors
(RAGE) have been shown to play a key role in the pathogenesis
of DN. AGEs modified proteins activate MAP kinase and induce
apoptosis. Inhibition of MAP kinase reduces the apoptotic effect of
AGE modified-BSA. Exposure to AGE-BSA is associated with Akt
dephosphorylation and transcriptional activation of FOXO4 lead-
ing to an increase in the expression of Bim, an effector protein of
apoptosis (51). Elevated glucose levels can also result in podocyte
depletion via autophagy. Thus, in a recent study it was shown
that high glucose promotes autophagy of podocytes by enhanced
expression of autophagic mediators LC3-2 and beclin-1 (52). Inhi-
bition of glucose-induced autophagy by N -acetylcysteine argues
FIGURE 2 | A simplified scheme that describes hyperglycemia
mediated alterations in various cellular events resulting in apoptosis
of podocytes.
for a role of ROS in promoting podocyte autophagy. Figure 2 pro-
vides a simplified scheme for the direct action of hyperglycemia
on podocyte apoptosis.
ROLE OF INSULIN SIGNALING ON PODOCYTE FUNCTION
AND APOPTOSIS
Diabetes mellitus is characterized by reduced insulin signaling in
cells resulting from insulin resistance (hallmark of type 2 DM) or
lack of insulin secretion (hallmark of type 1 DM) or a combination
of both mechanisms. Podocytes express the insulin receptor and
are the main target of insulin action in the glomerulus, exhibit-
ing insulin-dependent PI3K and MAPK signaling both in vitro
and in vivo (43). Podocytes respond with increased glucose uptake
upon exposure to insulin. The podocyte response to insulin is
associated with remodeling of the actin cytoskeleton via GTPase
RhoA activation and inhibition of CDC42 and this may allow
for contraction of podocytes in response to increased glomeru-
lar pressure and filtration (43). Since, insulin has a critical role in
normal podocyte function, it is expected that insulin-dependent
cellular activities are altered in podocytes in DM. In the animal
models of streptozotocin-induced insulinopenic DM and type 2
DM, glomerular insulin signaling is lost early in the progression
of diabetic kidney disease (53). In non-diabetic humans, insulin
resistance per se is associated with proteinuria. In the setting of
DM, insulin resistance predicts the incidence of nephropathy in
type 1 and type 2 DM (54). Podocyte-specific deletion of insulin
receptor causes several glomerular abnormalities including albu-
minuria, increased glomerular matrix accumulation, thickening
of GBM, loss of podocyte morphology, and apoptosis (55). It
is noteworthy that all the above manifestations occurred under
normoglycemic conditions. It was also shown that chronic expo-
sure of podocytes to high glucose leads to decreased insulin
responsiveness via increasing Src homology two domain con-
taining phosphatase1 (SHP1) that binds to the insulin receptor
and prevents downstream signaling (56). SHP1 associates with
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insulin receptor β to dampen insulin-stimulated Akt and extracel-
lular signal-regulated kinase ERK phosphorylation. Analogously,
in type 1 diabetic Akita mice, Akt and ERK phosphorylation were
reduced in renal podocytes and this renal insulin resistance was
associated with elevated SHP1 expression. The renal insulin resis-
tance in Akita mice was associated with foot process effacement
and podocyte apoptosis compared with control littermate mice.
Overexpression of dominant-negative SHP1 in podocytes pre-
vented deleterious effects of high glucose and restored insulin
sensitivity (57). Impaired insulin signaling either by altered levels
of fatty acids in DM and related metabolic syndrome or pro-
inflammatory cytokines (IL6 and TNF-α) that accumulate during
insulin resistance is implicated in podocyte injury (58). Alterna-
tively, it was shown that ubiquitination and consequent degrada-
tion of insulin receptor substrate-1 is enhanced in hyperglycemic
conditions, which manifests as impaired insulin signaling (53).
Podocytes from db/db mice failed to respond to insulin treatment
as evidenced by decreased AKT phosphorylation and susceptibility
to cell death (59). Hence, resistance to insulin and susceptibility
to cell death may partially account for the decreased podocyte
number seen in early DN. The podocyte protective properties of
thiazolidinediones (60) also support the argument that restoring
insulin sensitivity in podocytes can ameliorate the podocytopenia
observed in DM (61).
THE ROLE OF mTOR IN PODOCYTE APOPTOSIS
The mammalian target of rapamycin (mTOR) pathway is impor-
tant for cellular sensing of nutrient and growth factors and
cellular stress. mTOR nucleates at least two distinct multi-
protein complexes, mTOR complex 1 (mTORC1) and mTOR
complex 2 (mTORC2). The precise role of mTOR in the
podocyte remains controversial. Activation of mTORC1 activ-
ity in podocytes resulted in proteinuria, loss of podocytes and
changes in the components of GBM; all these alterations were
modulated by treatment with rapamycin, an inhibitor of mTOR
(54). In contrast, inhibition of mTORC1 with rapamycin treat-
ment manifests as increased proteinuria and glomerulosclerosis in
patients and animal models (54). A strong evidence for the role of
mTOR in podocyte biology is provided by a study from Godel
et al. (62). At 4 weeks of age, mTORC1 knockout mice devel-
oped significant albuminuria. Increased lethality was noticed at
8 months of age and was attributed to proteinuria and associated
weight loss. Genetic deletion of mTORC1 in mouse podocytes
induced proteinuria and progressive glomerulosclerosis. Ultra-
structural analyses revealed progressive podocyte foot process
broadening and effacement in mTORC1 knockout mice and indi-
cating that mTORC1 is required to maintain podocyte function
and glomerular architecture. The mTORC1 loss-of-function phe-
notype was reported to be similar to the phenotype observed in
podocyte-specific insulin receptor deficient mice (55). Further-
more, simultaneous deletion of both mTORC1 and mTORC2 from
mouse podocytes resulted in massive foot process effacement and
proteinuria. These findings reveal the importance of both mTOR
complexes for podocyte homeostasis. In contrast, increased mTOR
activity was contemporaneous with early glomerular hypertro-
phy and hyperfiltration in humans with DN. Curtailing mTORC1
signaling in mice podocytes prevented glomerulosclerosis and
significantly ameliorated the progression of DN. It is noteworthy
that rapamycin treatment was found to be therapeutically bene-
ficial in patients who had undergone renal replacement therapy
(63, 64). In the background of DN, a more context based under-
standing of role of mTOR needs to be delineated. We speculate
that under normal conditions, mTOR activity is essential for nor-
mal podocyte function. However, in DM elevated mTOR activity
will also mediate adverse effects. Since mTOR regulates size of
the cell, the role of mTOR on hypertrophy of podocytes in the
early course of DN needs to be delineated. Recent studies report
that mTOR hyperactivation is associated with Notch activation
in podocytes, which has been shown to drive development of
glomerular disease (65, 66).
THE ROLE OF NOTCH SIGNALING IN PODOCYTE APOPTOSIS
Notch constitutes an evolutionarily conserved intracellular sig-
naling pathway that determines the cell fate. Notch pathway is
activated by interaction between Notch receptors and cognate
ligands from neighboring cells. Activated notch receptors are
cleaved by γ-secretase and the intracellular domain translocates
into the nucleus and stimulates transcription of target genes.
Among the four types of Notch receptors (Notch1-4), types 1
and 2 are activated during mammalian nephrogenesis (67) and
are dormant in the mature renal glomerulus (68). It was reported
that Notch1 was reactivated in kidney specimens from patients
with DN and focal segmental glomerulosclerosis (FSGS) and that
reactivation of Notch1 correlated with the development of pro-
teinuria due to podocyte apoptosis (65, 69). Whereas knockdown
of Notch2 increased apoptosis of podocytes, a Notch2 agonistic
monoclonal antibody protected injured podocytes from apoptosis
via enhanced activation of AKT (70). Hence, these studies suggest
that Notch signaling plays a role in pathogenesis of glomerular
diseases and represents a novel therapeutic target.
TGF-βMEDIATES PODOCYTE APOPTOSIS
Diabetic kidney disease is associated with increased expression of
TGF-β1 in glomerular and tubular epithelial cells. TGF-β is a pro-
totypical and multifunctional cytokine involved in many cellular
processes including cell growth, differentiation, and apoptosis. The
TGF-β cytokine family include TGFβ1, TGFβ2, and TGFβ3, and
these ligands bind to the type II receptor, which recruits and phos-
phorylates the type I receptor. The type I receptor then phospho-
rylates receptor-regulated SMADs (Sma and Mad Related Family
proteins; SMAD1, SMAD2, SMAD3, SMAD5, and SMAD8) that
can bind the co-mediator SMADs (SMAD4 and SMAD10). The
complex of receptor-regulated SMADs and co-mediator SMADs
accumulate in the nucleus, act as transcription factors and regulate
target gene expression. There are two inhibitory SMADs (SMAD6
and SMAD7) that regulate TGF-β signaling in a negative feedback
manner. Several lines of evidence suggest increased levels of TGF-β
in injured kidneys from experimental animals and in humans with
chronic kidney diseases (71, 72). Whereas TGF-β initiates and ter-
minates tissue repair and wound healing, sustained production of
TGF-β triggers the development of tissue fibrosis, accumulation
of various components of the extracellular matrix (ECM), and
glomerulosclerosis (73). An in-depth discussion of the fibrogenic
role of TGF-β1 is beyond the scope of this review.
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Evidence for a pathogenic role for TGF-β1 in promoting
podocyte apoptosis was obtained in a study by Schiffer et al.
(24). Apoptosis of podocytes was observed in TGF-β1 trans-
genic mice and activation of p38 MAP kinase and caspase-3 was
required for TGF-β1 mediated podocyte apoptosis. This study
also highlighted the fact that apoptosis of podocytes occur as
an early event in the course of progressive glomerulosclerosis
and precedes mesangial expansion. Smad7 expression is strongly
induced both in cultured podocytes treated with TGF-β and
in podocytes from TGF-β1 transgenic mice (24). Unlike TGF-
β1, Smad7 induces podocyte apoptosis by inhibiting nuclear
translocation and transcriptional activity of NF-κB. However,
co-expression of Smad7 has an additive effect on the TGF-β1
mediated podocyte apoptosis (24). Recently, an alternative theory
was put forward for TGF-β1 mediated podocyte injury. TGF-β1
increases mitochondrial membrane potential and oxygen con-
sumption rate via mTOR pathway, resulting in increased ROS
generation and podocyte injury (74). TGF-β receptor-SMAD
axis dependent mitochondrial Nox4 activation and ROS produc-
tion impedes mitochondrial function and apoptosis (75). Sev-
eral pathological mediators such as angiotensin II, VEGF, and
Gremlin aggravate hyperglycemia-induced podocyte injury by a
TGF-β dependent signaling pathway (76–78). Nevertheless, it is
intriguing that anti-TGF-β interventions are only inconsistently
associated with reduction of albuminuria in experimental models
of DN (79).
EPITHELIAL-TO-MESENCHYMAL TRANSITION AS A
MECHANISM FOR PODOCYTOPENIA IN DIABETES MELLITUS
Epithelial-to-mesenchymal transition (EMT) is an orchestrated
series of events in which cell–cell and cell–ECM interactions are
altered to release epithelial cells from the host tissue, the cytoskele-
ton is reorganized to enable these cells to migrate, and an altered
transcriptional program is induced to maintain these cells in a
mesenchymal phenotype (80). EMT is a fundamental process that
occurs during many stages of development in which the embryonic
epithelium gives rise to the mesoderm, and in delamination of the
neural crest, which produces a population of highly mobile cells
that migrate to and are incorporated into many different tissues
(80). Nevertheless, EMT is potentially destructive if deregulated
and unrestrained EMT is an integral component of the pathology
of tumor metastasis and tissue fibrosis (81).
In response to injury, podocytes are capable of undergoing
a phenotypic switch to attain an embryonic form by shedding
their specialized epithelial characteristics and by acquiring mes-
enchymal features (81). It is conceivable that podocytes after
undergoing EMT abandon their complex morphological archi-
tecture and relinquish their highly specialized functions, which
impairs the integrity of GFB, leading to the onset of proteinuria.
Although it is debatable whether EMT contributes to decreased
podocyte density in diabetic kidney disease, identification of sig-
nificant amount of viable urinary podocytes from both experi-
mental models of DN and from patients with DN suggest that
podocyte dropout might be caused by decreased podocyte adhe-
sion, which is a potential consequence of EMT (20, 82). Podocytes
were identified by immunostaining for nephrin and podocin in
the urine from passive Heymann nephritis model of membranous
Table 1 | List of EMT markers that either decrease or increase in
podocytes upon treatment with GH andTGF-β1.
Attenuated markers Enhanced markers
E-cadherin ZEB2
P-cadherin Snail
Zonula Occludens-1 (ZO-1)
Nephrin
FSP1
Desmin
α-Smooth Muscle
Actin
Vimentin
Nestin
MMP9
nephropathy and in the streptozotocin model of DN in rats (18,
82). Podocytes isolated from urine readily adhere to tissue cul-
ture plates and are able to proliferate under standard cell cul-
ture conditions. The appearance of podocytes in urine questions
the quality of adhesive proteins that maintain the integrity of
podocytes with GBM. Podocytes adhere to the GBM, which is
primarily comprised of collagen IV and laminins. Proteins belong-
ing to the integrin family are crucial for cellular interactions with
ECM components of GBM. α3β1 integrin is an adhesion recep-
tor for laminins and type IV collagen, and expressed primarily on
podocytes. Decreased α3β1 integrin expression was observed in
podocytes exposed to high glucose concentration (83). Attenua-
tion of α3β1 integrin expression in podocytes from both short-
and long-term diabetic rats argues for a role for podocyte detach-
ment from GBM in DN (84, 85). In a retrospective cross-sectional
analysis, greater amounts of fibroblast-specific protein-1 (FSP1)-
positive podocytes were observed in urinary sediments of diabetic
patients with macroalbuminuria than in those with normoal-
buminuria (86). FSP1-positive podocytes selectively expressed
Snail1, a known trigger for EMT. This study suggests that appear-
ance of FSP1 in podocytes of patients with DM is associated with
more severe clinical and pathological findings of DN and correlates
with podocyte detachment consequent to the EMT process. A list
of epithelial and mesenchymal markers in podocytes is provided
in Table 1.
A PATHOGENIC ROLE FOR TGF-β1 IN PODOCYTE EMT
In the earlier section, we discussed the role of TGF-β1 in podocyte
apoptosis. Although the effect of TGF-β1 on podocyte apop-
tosis and thickening of GBM has been known for some time,
evidence for the role of TGF-β1 in inducing phenotypic con-
version of podocytes to motile mesenchymal cells was provided
by study from Li et al. (87). TGF-β treatment in conditionally
immortalized mouse podocytes attenuated the expression of P-
cadherin, ZO-1, and nephrin, while promoting the acquisition
of mesenchymal markers such as Snail, FSP1, and Desmin. As
nephrin, P-cadherin, and ZO-1 are important components of SD
of podocytes, decreased expression of these proteins impairs the
integrity of the SD leading to foot process effacement and altered
podocyte permselectivity to albumin (87). TGF-β1 induced Snail
expression was implicated in initiating EMT of podocytes and
ectopic expression of Snail suppressed P-cadherin and nephrin
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in podocytes (87). Further insights into the role of TGF-β1 in
podocyte EMT was obtained by a study from Herman-Edelstein
et al. (88). In this study, the authors employed immortalized
human podocytes and demonstrated that treatment with TGF-
β1 resulted in retraction and shortening of foot processes and
contraction of the podocyte cell body. In addition to these mor-
phological changes, exposure to TGF-β1 resulted in a dedifferenti-
ated phenotype in podocytes with enhanced motility (88). A dose-
and time-dependent attenuation of podocyte epithelial mark-
ers and acquisition of mesenchymal markers and ECM compo-
nents was observed following treatment with TGF-β (88). Besides
regulating the expression of EMT markers, TGF-β1 treatment
decreased the expression of adhesive proteins of the podocytes.
In nephrotic rats, TGF-β1 suppresses the glomerular expression
of α3 integrin (89). Since the α3 integrin subunit has a pivotal
role in regulating podocyte adhesiveness to GBM, it is specu-
lated that loss of α3 subunit expression results in the detach-
ment of podocytes from GBM. Furthermore, when cultured
podocytes were treated with TGF-β1, α3β1 integrin expression
was decreased with concomitant reduction in podocyte adhe-
sion (90). To summarize, TGF-β1 exerts multiple effects on
podocytes; (i) TGF-β1 reduces podocyte adhesion to the GBM
via down regulation of α3β1 integrin; (ii) TGF-β1 induces EMT
of podocytes by attenuating epithelial markers and acquisition
of mesenchymal markers resulting in podocyte depletion; (iii)
TGF-β1 impairs the architecture of SD and alters the perms-
electivity of podocytes, and (iv) TGF-β1 increases apoptosis of
podocytes (88).
ROLE OF GROWTH HORMONE IN EMT AND APOPTOSIS OF
PODOCYTES
In type 1 DM, insulin deficiency results in impaired hepatic IGF-1
production but increased secretion of hepatic IGFBP1. Increase
in IGFBP1 leads to inhibition of IGF-1 action at the cellular level
and in concert with the lower levels of hepatic IGF-1 production
results, via a negative feedback mechanism, in increased growth
hormone (GH) secretion by the pituitary gland and higher cir-
culatory levels of GH (91). GH excess in both humans and in
transgenic animal models is characterized by significant struc-
tural and functional changes in the kidney. In humans, a direct
relationship has been noted between the activity of the GH/IGF-1
axis and renal hypertrophy, macroalbuminuria, and glomeru-
losclerosis. Conversely, states of GH deficiency or ablation of GH
receptor or its activity confer a protective effect against DN (92).
A recent study revealed that podocytes express GH receptor and
respond to GH by activation of JAK/STAT signaling (93). Kumar
et al. demonstrated that podocytes respond to GH by inducing
expression of zinc-finger E-box binding protein (ZEB2), a tran-
scription factor that mediates EMT (94). It was also shown that
GH treatment resulted in loss of E- and P-cadherin expression
and consequently attenuated podocyte permselectivity to albumin
(94). Abrogation of ZEB2 expression prevented GH dependent
EMT changes in podocytes (94). In ongoing studies, GH adminis-
tration to rats increased enhanced apoptosis and EMT, decreased
podocyte count, and increased proteinuria (Kumar et al., under
review). The proposed mechanisms of GH and TGF-β mediated
injury to podocytes are summarized in Figure 3.
FIGURE 3 |TGF-β and growth hormone (GH) induce
epithelial-to-mesenchymal (EMT) transition of podocytes via activation
of Snail1 and ZEB2 genes, respectively. Both TGF-β and GH induce
expression of TGF-β induced protein (TGF-βip). In addition to inducing EMT,
these transcriptional factors also suppress expression of slit-diaphragm
proteins resulting in increased podocyte permeability to plasma proteins.
CONCLUDING REMARKS
Our understanding of podocyte biology has increased significantly
in the past decade, and we are learning more about novel medi-
ators of podocyte injury, apoptosis, and their detachment. The
molecular mechanism(s) of podocytopenia in diabetic mellitus is
now better understood. A majority of cellular events in DM exert
toxicity by inducing podocyte apoptosis via increase in mitochon-
drial and/or cytoplasmic ROS (Figure 2), suggesting that the ROS
pathway could be a pharmacological target to combat podocyte
apoptosis. Snail and ZEB2 are key transcriptional factors impli-
cated in initiating EMT and are induced by TGF-β1 and GH,
respectively (Figure 3) (87, 94). It is envisaged that a greater insight
into podocyte biology will lead to better therapeutic options for
improving the survival and quality of life of patients with diabetic
nephropathy.
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